{"ticker": {"uuid": "de72e54f-253a-4fd9-9a77-4075aac4d646", "symbol": "VTGN", "name": "VistaGen Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPWXVhWXVUMExaQ205SGU1QUdEdkFxZjVlb3dLSzFmWXFqRnJHWS1iRVBHUXlpMElUYXRGR3RRN21aX19UUVo3NEF1a0VMQWFBamhWVk1DQXlxQ0x4ajlPSnRDdFJBeHpFd1MyVXBjZlFUT2JjYVNoNkFMcHZoMnZ3bzh4MEFOVERFTGd2bGRNcG5VSUw0ZHNNOVlyNlhxdw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:22:20+00:00", "published_display": "15 Jul 2026 09:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals \u2013 But Retail Believes It\u2019s Oversold, Says Won\u2019t Panic-Sell", "summary": "Shares of Vistagen (VTGN) plummeted over 71% after its anxiety therapy, Fasedienol, failed to meet primary and secondary endpoints in a late-stage trial. Despite the setback and the treatment showing no significant difference from placebo, the company plans to discuss a potential", "url": "https://stocktwits.com/news-articles/markets/equity/this-stock-lost-71-of-value-after-anxiety-therapy-missed-key-goal-but-retail-believes-it-s-oversold-says-won-t-panic-sell/cZ1QjLpR705", "source_name": "Stocktwits", "published_at": "2026-07-11T14:11:21", "published_display": "11 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for VistaGen Therapeutics Inc. on July 2 with Investing.com as the source. It concisely conveys the release of this financial disclosure.", "url": "https://ng.investing.com/news/stock-market-news/form-4-vistagen-therapeutics-inc-for-2-july-93CH-2585057", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T00:09:30", "published_display": "07 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating, Maintains Target Price $1", "summary": "Stifel has reiterated its Hold rating on VistaGen Therapeutics (VTGN.US) and maintained its price target of $1.00. This suggests the firm's continued neutral stance on the stock, with an expectation that its value will remain around the current target.", "url": "https://www.moomoo.com/news/post/72500274/stifel-maintains-vistagen-therapeutics-vtgnus-with-hold-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-06T11:10:35", "published_display": "06 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTGN - Vistagen Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Vistagen Therapeutics Inc (VTGN), along with comprehensive financial data, stock performance metrics, and analyst recommendations. It details key figures such as market capitalization, income, sales, EPS, and various fi", "url": "https://finviz.com/stock?t=VTGN&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T02:40:47", "published_display": "04 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Vistagen Therapeutics, Inc. \u2013 NASDAQ:VTGN", "summary": "This article provides financial information for Vistagen Therapeutics, Inc. (NASDAQ: VTGN), specifically focusing on its price to sales forward metric. It appears to be a stub or an incomplete financial data page from TradingView, showing no specific data values but indicating th", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T21:09:37", "published_display": "03 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Vistagen Therapeutics, Inc. \u2013 NASDAQ:VTGN", "summary": "The article references the \"Enterprise value to revenue forward\" metric for Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on the TradingView platform. It provides some basic stock market information for VTGN, including its NASDAQ listing and current market status. The content appear", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T11:40:47", "published_display": "03 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Vistagen Therapeutics, Inc. \u2013 NASDAQ:VTGN", "summary": "The article displays the \"Price to book forward\" financial metric for Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on the TradingView platform. It presents a simple table showing the period, value, change, and percentage change for this specific financial indicator. The content is ", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T04:10:41", "published_display": "03 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen (VTGN) CEO adds 36,818 ESPP shares, now holds over 54,000 directly", "summary": "Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired 36,818 shares of common stock through the company's Employee Stock Purchase Plan at $0.1921 per share. This acquisition, exempt under Rule 16b-3, increases his direct holdings to 54,846 shares. Additionally, 20,87", "url": "https://www.stocktitan.net/sec-filings/VTGN/form-4-vistagen-therapeutics-inc-insider-trading-activity-f4e1f526663d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:41", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen (VTGN) Chief Legal Officer adds 36,818 ESPP shares in Form 4 filing", "summary": "Vistagen Therapeutics' Chief Legal Officer, Reid G. Adler, increased his holdings by acquiring 36,818 shares of common stock through the company's 2019 Employee Stock Purchase Plan. This transaction, executed on June 30, 2026, at an average price of $0.1921 per share, was exempt ", "url": "https://www.stocktitan.net/sec-filings/VTGN/form-4-vistagen-therapeutics-inc-insider-trading-activity-32816654af87.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:41", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares", "summary": "Vistagen Therapeutics, Inc.'s Chief Financial Officer, Nick B. Tressler, acquired 11,712 shares of common stock on June 30, 2026, through the company\u2019s 2019 Employee Stock Purchase Plan at $0.1921 per share. Following this transaction, his direct holdings amount to 11,712 shares,", "url": "https://www.stocktitan.net/sec-filings/VTGN/form-4-vistagen-therapeutics-inc-insider-trading-activity-0e64708fc868.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:41", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder", "summary": "Vistagen announced topline results from its PALISADE-4 Phase 3 trial for fasedienol, which did not meet primary or secondary endpoints for treating social anxiety disorder in the overall population. However, a post-hoc analysis showed statistically significant improvement in pati", "url": "https://finance.yahoo.com/healthcare/articles/vistagen-announces-topline-post-hoc-120000253.html", "source_name": "Market source", "published_at": "2026-07-01T22:39:52", "published_display": "01 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen\u2019s fasedienol fails second Phase III social anxiety trial, clouding acute treatment strategy", "summary": "Vistagen Therapeutics announced that its fasedienol candidate failed a second Phase III trial (PALISADE-4) for social anxiety disorder, again missing its primary endpoint. This result puts pressure on the company to identify a credible path forward with the FDA, especially as the", "url": "https://allsci.com/news/clinical-trials/vistagens-fasedienol-fails-second-phase-iii-social-anxiety-trial-clouding-acute-treatment-strategy/", "source_name": "AllSci", "published_at": "2026-07-01T09:41:26", "published_display": "01 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Vistagen Therapeutics, Inc. (VTGN) on behalf of investors who purchased securities prior to April 1, 2024, and still hold them. The investigation aims to determine if Vistagen's officers and/or directors", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-vistagen-therapeutics-inc-0", "source_name": "The National Law Review", "published_at": "2026-07-01T07:39:22", "published_display": "01 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss", "summary": "Vistagen Therapeutics' Phase 3 PALISADE-4 trial for its intranasal fasedienol in acute social anxiety disorder missed its primary and secondary endpoints. However, a post-hoc analysis identified a statistically significant benefit in patients with very severe social anxiety, prom", "url": "https://www.benzinga.com/news/health-care/26/06/60197274/penny-stock-vistagen-keeps-regulatory-plans-alive-despite-anxiety-study-miss", "source_name": "Benzinga", "published_at": "2026-06-30T17:10:57", "published_display": "30 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder.", "summary": "VistaGen Therapeutics (VTGN) released topline data and post-hoc analysis results from its Phase 3 Palisade-4 trial for Fasedienol, a drug for acute social anxiety disorder. The trial, using a public speaking challenge model, did not show a statistically significant difference bet", "url": "https://www.bitget.com/amp/news/detail/12560605483694", "source_name": "Bitget", "published_at": "2026-06-30T14:39:21", "published_display": "30 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen (NASDAQ: VTGN) Phase 3 fasedienol trial misses main goal but shows severe-SAD signal", "summary": "Vistagen's Phase 3 PALISADE-4 trial for intranasal fasedienol in social anxiety disorder (SAD) missed its primary and secondary endpoints in the overall patient population. However, a post-hoc analysis revealed a nominally statistically significant improvement in a subgroup of pa", "url": "https://www.stocktitan.net/sec-filings/VTGN/8-k-vistagen-therapeutics-inc-reports-material-event-e81fcc1b20bb.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:10:57", "published_display": "30 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup", "summary": "Vistagen (VTGN) announced that its PALISADE-4 trial did not meet its primary or secondary endpoints for social anxiety disorder (SAD). However, a post-hoc analysis revealed a nominally significant benefit in a subgroup of patients with very severe SAD. The company plans to engage", "url": "https://www.tradingview.com/news/tradingview:60eda03715aed:0-vistagen-reports-palisade-4-miss-on-primary-endpoints-positive-post-hoc-signal-in-very-severe-sad-subgroup/", "source_name": "TradingView", "published_at": "2026-06-30T12:10:57", "published_display": "30 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen fails another phase 3 anxiety trial, spies path forward", "summary": "Vistagen's social anxiety disorder drug candidate, fasedienol, has failed another phase 3 trial, PALISADE-4, missing its primary and secondary endpoints. Despite the setback, the company plans to pursue FDA approval by leveraging post hoc analysis data from a subpopulation of pat", "url": "https://www.fiercebiotech.com/biotech/vistagen-fails-another-phase-3-social-anxiety-trial-spies-path-market", "source_name": "Fierce Biotech", "published_at": "2026-06-30T09:48:00", "published_display": "30 Jun 2026 09:48", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen\u2019s fasedienol fails main test, but one subgroup showed a signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaXFETmU1NERHdFBZYzV3T1EtcGRoaXhDYnZySFBZM1ZLV2RZenVYUjBnU001MGtsSGF4SW5WS3pzVFNPanZhYzJUeHhYMlNoZHJMZ1hfMGJXa2toaUR1ZG10ZHZSckhfck0wMWpjRjF3SjZ0ZmRMOXdnSzN0b3FiN3JsLUZsVHctXzAtbUlyYU92QzExUGc3VHFRUmdna1ZWOERxNnRkZGUtRVdCd2pJQlBHN2RsS0N3eGo5YmZKRko?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics, Inc. Actuals & Estimates (NASDAQ:VTGN)", "summary": "This article provides an overview of Vistagen Therapeutics, Inc. (VTGN) financial actuals and analyst estimates, including its current stock price, market capitalization, and historical performance. It also details quarterly earnings, revenue, and future earnings report dates. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:40:15", "published_display": "26 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics, Inc. Actuals & Estimates (BOATS:VTGN)", "summary": "This article provides financial actuals and estimates for Vistagen Therapeutics, Inc. (VTGN) on the BOATS exchange, including analyst forecasts, historical price data, and upcoming earnings information. It details the company's financial performance, such as recent earnings and r", "url": "https://www.tradingview.com/symbols/BOATS-VTGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:38", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTGN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Vistagen Therapeutics, Inc. (VTGN) stock, including analyst price targets and ratings. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The report also addre", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:19", "published_display": "25 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics\u2019 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth", "summary": "Vistagen Therapeutics Inc. is facing increased execution risks due to its planned March 2026 workforce reduction, which aimed to conserve cash and advance trials for fasedienol. This downsizing could lead to a loss of institutional knowledge, lower employee morale, and hinder the", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VTGN-Q/pressreleases/2528780/vistagen-therapeutics-2026-workforce-cuts-raise-execution-risks-and-threaten-long-term-growth/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T03:09:16", "published_display": "19 Jun 2026 03:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics directors to step down after 2026 annual meeting", "summary": "Vistagen Therapeutics announced that two board members, Margaret FitzPatrick and Dr. Joanne Curley, will not seek re-election at the company\u2019s 2026 Annual Meeting of Stockholders. Both will continue to serve until their terms conclude at the meeting. This news follows a period of", "url": "https://m.uk.investing.com/news/sec-filings/vistagen-therapeutics-directors-to-step-down-after-2026-annual-meeting-93CH-4734114?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T02:39:33", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Vistagen Therapeutics (NASDAQ:VTGN) Must Use Its Cash Wisely", "summary": "Vistagen Therapeutics (NASDAQ:VTGN) is burning through cash at a concerning rate, with a cash burn of US$61m against US$45m in reserves as of March 2026, giving it only about 9 months of cash runway. The company's cash burn increased by 43% last year, and its cash burn relative t", "url": "https://www.sahmcapital.com/news/content/heres-why-vistagen-therapeutics-nasdaqvtgn-must-use-its-cash-wisely-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-18T02:39:32", "published_display": "18 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Vistagen Therapeutics Inc (VTGN). It notes that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents curr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vtgn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:00:17", "published_display": "18 Jun 2026 01:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting", "summary": "Vistagen Therapeutics, Inc. announced that two of its board members, Margaret FitzPatrick and Dr. Joanne Curley, will not seek re-election at the company's 2026 Annual Meeting of Stockholders. Both directors will continue to serve until their current terms conclude at the meeting", "url": "https://www.stocktitan.net/sec-filings/VTGN/8-k-vistagen-therapeutics-inc-reports-material-event-c05f165242e7.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:40:17", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOb2o0TkhvdXBJa1JJc0lIZWZpelZWbmlaVkEzbjhlOVd4aWRJcE13V2hHX2F3Q3duV2lqNFl0eEJhX21PRGYtTjRIV3RnYmhjeDUxeS16aDhFa0RJY3BsTFNSQzhESG5nZ0ptN0hCc01LYTl5aFYwMTR1cWdqdmtMa3BFNXVYRUhqek5mT0prbHNtOWNiaTZJQjBEOHNOVm9tN3JjV3ozLVdiXzZ1UHRsM2llcmM2X2N3UkRPMzlVOXFaQlprbjZqbkowM1dTdUc1dUdGZA?oc=5", "source_name": "Business Wire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 data for Vistagen intranasal anxiety drug due this month", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX1JwYmFpMDRZNXBRUVk5aDdGcVJ6UEZtb2tVN2FmbVlMR1k3Zk1ISThyaTNGaUxNUDB5aGRHdEcwclJjaUpGUTBpYlRyTzctakxHcjM3a0RidlZPVExRb1BSQ2tzbUtudGhBN3NCUmxzVmc4alJlS3ROUjBWTWtXWnc2U2ttclNDMHgwQy1mT3U1Z3g0RUFIQS1BOVM2VW1HbEhTcjFEZHRDczd1bkFLMmh4VFFjVDJkdk5n?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings | VTGN Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOcGpPZXNfNFV3Q2VXNlBNSHc0NEJZVUJ2bVBCNy1PczZYZzRjS2xsdUdiQU9IaFVyT2VnUlFrYnVRdmJjREtpaXdZc2ZfLUYtN3ZuWE1LeFJRU0lBSm1oTjZvdFdaUF9WV0ZqQnlPcGRoTDFqSzhvUlVRYVNFTmJfT2o0ckhxWVBNWmE5RmRmQU9WZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics Says Fasedienol Clinical Program Exceeds ICH Exposure Thresholds", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vistagen-therapeutics-says-fasedienol-clinical-103808726.html", "source_name": "MT Newswires", "published_at": "2026-06-10T10:38:08+00:00", "published_display": "10 Jun 2026 10:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vistagen-achieves-minimum-ich-safety-123000936.html", "source_name": "Business Wire", "published_at": "2026-06-09T12:30:00+00:00", "published_display": "09 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNUdmU3B4MGNqVkY5SlUtbW9nUHhXSVNtZkowWlJsUVZ5ZjhjQkplSzJiZWtjeW1CM0tPb0xCREk4RUxGQ1Z6WGFTWWdLbHdMb21XRGtDZlo2MUtCaks5OTYta2NFR1huT0tYYVFHdFhHSGFxRklVMEQ2UDZpeS0xaVB3bkJ1QlVjcldOWGU1S1BITUNfSUI4R2FPMUluQ1FkcWc1STFvX3hyTGdMVWc5RGctQVA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNOGo1Q0hGV3Y3R3VweGdwUDlGN1lScU1MUUIwLXZTV2pLRmNLYm96VEV5cEF4aExlY3FnYktFSzhJSXpwTlhYNHVKQnhtaU9zSlNfX0xBVTlwMUF5LXFFdHRmLUZORjV0MXY0eW5BNjI0ZXlLek9FNklvRVRMMXFZZ19oWklScXhGRjBwTGQzeTNTc3RlX2o0a1VmOU1GaUVjVVh5WmNxaEtzNXRC?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Public-speaking challenge study ends; Vistagen data due this quarter", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPWVRQTzBhdzVSVV9VUDZ1LXRadjZ6Uy1ONFF0bFgwci1xMC1zRFhnc1QtT2NPelh5elB6aEY3VnF2djcxb0tVd21NMkFKUGtxY2dCTXFETHh0OUNveDc1Mk5ZWldfUjZMUlF1Tl92SWozUEIwNm9tcUxPaDJhMlJkeC1zZ1MwZ080M0ViLTAtSUlRNWxuTW9NaTM5VjVtZ29nQnJWdmcyc2I1X0RQUWhwNHhLQnd0bDNhM3o3Tg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5IMlg1RGl0WjdTMF94MjFhZ2lkS0x0M1FyUTliTjBZbkNuNEtuOFF6ZmdqTno2Ty1vZkxyMGwwV3FfOU1pOUlBM1JoUndaV1U3TkhvZ2N3Yk1SVHc3?oc=5", "source_name": "Schubert Jonckheer & Kolbe", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwJBVV95cUxNSHYybTdtTUVRZUdIVFh0Z0FNak5ZNE1WaEhPRTRPNEM1ajU2eG5zOFVLV3NXbkpfZ0lfR1NLWGVtV0VHTEc3MXE0RS1tM0NDV1p3ckduSjRkYkJPN0FQOFMtZ0ZaVENhaHdCaTJVY0RuNHZhSnBOWDNJTE1SYXdKNjJfbDliMEdXRGt2NFdYSHplQjc0bzZMMzctcE5LTkpSQ1o4TVhBSjdIRVZYdWgtUHdwc2pyWVpaMi1mNEl3RUw2VU1jYkRmYzZSa3NndnZ1dUUwd2NieVNGQUd5QUVmVXRmNGk5b3N5T050aGhNa0lzbmNYTzlXZGJYSmpVa19xek8zNUxEUXZqbDBmOUxCYURXdWpmdnNJbml1RXZpYVdCaW4yb25JWHJEaXFPQllheEduMVpoUHlndGM?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQQVJsNjJkX2NUSzRGNU02SnYzV2tzRVA4ZzRJTHZTQkZKMkxMSXctRzNzUWFsWTltckFkU0dvVTBZM2NUVEplZUxaSEVtVTJadGZZQ0w5MEdOQ0ZxLU0zUkI5d1BsUVpPekt0Y1R4aXVyclNUeTJzcjA5bzdWYlFTenFkRnd4YzA0bUVvbA?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vistagen Stock Tank 82% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVEZvZGVsN2tpeS1KVnM5YmxlYUtYUGlRc2hVR0F2ZTB6djlLOEZESXdkRDRHM3E3cUFBVHdYeFo0MVZzemlHU1BRa00zS2ZTd2M0OEJRVVU4enZtM3h2NVdYQVVWTWlKTjl6RWJOcHNyME1UZnJvWWM5STN6aFpfVEZQMFNmUUJjdnBJSUM0T1phNFJhSHEyMkpkNnFRZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-17T16:02:41+00:00", "published_display": "17 Dec 2025 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 (NASDAQ:VTGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbUdVRG02WGgxenQwVVhOWUFNSTMweDBRYnhKVUUtakJNai1yZWJrQTJ4dkZINEhHNmpNOVd2VlF5cFdfekl3UjR0NWtkTGlqdm4yeGFRUGdqLXhQaHRhT0RJNThta1YwRV9Jc1lhaU1uQzRFWlI2Z1ZGWngtbWdOaVBGS2JUeWtTVy1DQmJhaENrZHdVX1BBQkgwc1BJZGVuM0xwNVV6ZDJXY1k?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS0IzUlV4clR6V0tyRDlPVm45anhrRGtPZ2tHX1lZMFIwYmF6RWk0Q0dOMXQ4UHV5QWVMeTlFS2hteVd3YkRmMjUwRm1HWGdnalgwS1M0TFhDa3RUSTVYbnJXMWhOUzZoLXNQSXBkQkxYR1BycHVFOENxRm5CNG9tTTBCTXpCYUxpeHBHYnE4VUFTbTVLUEM3QjhCMGFWZWFHT3ZlM0M3SWUxZDFMMUQ0a0YwY1h5R19GSWVUV3Vn?oc=5", "source_name": "BioSpace", "published_at": "2025-06-17T07:00:00+00:00", "published_display": "17 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics (VTGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wbEJrb2FRZnYyOWtqaDlsdnQwdy1BcEM3Sl8xWUJtR1FvWnBnUWZrT2hYbUNLT3FsQ3A0dlBkRjFTTWVGQXM2eXlZRkIxT3JwTTdB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:34:57+00:00", "published_display": "25 Apr 2025 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxOUkxlTFFYXzVRYXFpWkh1N21UTDNSNzRLTGU4R1pfUmpGcmZsbTlyZi1KUmE0RzVIa05UZlhJZ3JlSk0tRFliQ2NSeGtzVzUydzN4WFVKZVMxdTFaaEVtM0lfdmFzUFl3VXJKXzdUWlAyZHZsSWlKMGNTNWtrOW5ZWm1ob3ZDWG5oRzRwbkJ5VmxoWVZBSVg0MlZVc3M2TjNpRnhSZml5T2FZOUljYTdTUEdocDRuV19oaG52TmxfdEJxZC1uLTJNY0xpSjlQQWdzbVYzWldjd0lZdHlNcFliUEhyOFRTeTdJVk44MmpVdnF0NFhueFRWYkFZZ1pTRGxpcHhUMktuS19hZw?oc=5", "source_name": "PR Newswire", "published_at": "2020-08-10T07:00:00+00:00", "published_display": "10 Aug 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics (VTGN) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1heUpFTmhRcC0zR3A2blVoQUxnUF84MkhuNWpHcEVOMEhmOGdlR0pOUEg1SkxSUDNSOTBHYWUxV0FPTEJyQ1JBaVVJVjBhdw?oc=5", "source_name": "Stock Titan", "published_at": "2020-08-08T11:57:33+00:00", "published_display": "08 Aug 2020 11:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPWXVhWXVUMExaQ205SGU1QUdEdkFxZjVlb3dLSzFmWXFqRnJHWS1iRVBHUXlpMElUYXRGR3RRN21aX19UUVo3NEF1a0VMQWFBamhWVk1DQXlxQ0x4ajlPSnRDdFJBeHpFd1MyVXBjZlFUT2JjYVNoNkFMcHZoMnZ3bzh4MEFOVERFTGd2bGRNcG5VSUw0ZHNNOVlyNlhxdw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:22:20+00:00", "published_display": "15 Jul 2026 09:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Stock Lost 71% Of Value After Anxiety Therapy Missed Key Goals \u2013 But Retail Believes It\u2019s Oversold, Says Won\u2019t Panic-Sell", "summary": "Shares of Vistagen (VTGN) plummeted over 71% after its anxiety therapy, Fasedienol, failed to meet primary and secondary endpoints in a late-stage trial. Despite the setback and the treatment showing no significant difference from placebo, the company plans to discuss a potential", "url": "https://stocktwits.com/news-articles/markets/equity/this-stock-lost-71-of-value-after-anxiety-therapy-missed-key-goal-but-retail-believes-it-s-oversold-says-won-t-panic-sell/cZ1QjLpR705", "source_name": "Stocktwits", "published_at": "2026-07-11T14:11:21", "published_display": "11 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for VistaGen Therapeutics Inc. on July 2 with Investing.com as the source. It concisely conveys the release of this financial disclosure.", "url": "https://ng.investing.com/news/stock-market-news/form-4-vistagen-therapeutics-inc-for-2-july-93CH-2585057", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T00:09:30", "published_display": "07 Jul 2026 00:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains VistaGen Therapeutics(VTGN.US) With Hold Rating, Maintains Target Price $1", "summary": "Stifel has reiterated its Hold rating on VistaGen Therapeutics (VTGN.US) and maintained its price target of $1.00. This suggests the firm's continued neutral stance on the stock, with an expectation that its value will remain around the current target.", "url": "https://www.moomoo.com/news/post/72500274/stifel-maintains-vistagen-therapeutics-vtgnus-with-hold-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-07-06T11:10:35", "published_display": "06 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTGN - Vistagen Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings information for Vistagen Therapeutics Inc (VTGN), along with comprehensive financial data, stock performance metrics, and analyst recommendations. It details key figures such as market capitalization, income, sales, EPS, and various fi", "url": "https://finviz.com/stock?t=VTGN&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-07-04T02:40:47", "published_display": "04 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Vistagen Therapeutics, Inc. \u2013 NASDAQ:VTGN", "summary": "This article provides financial information for Vistagen Therapeutics, Inc. (NASDAQ: VTGN), specifically focusing on its price to sales forward metric. It appears to be a stub or an incomplete financial data page from TradingView, showing no specific data values but indicating th", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T21:09:37", "published_display": "03 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Vistagen Therapeutics, Inc. \u2013 NASDAQ:VTGN", "summary": "The article references the \"Enterprise value to revenue forward\" metric for Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on the TradingView platform. It provides some basic stock market information for VTGN, including its NASDAQ listing and current market status. The content appear", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T11:40:47", "published_display": "03 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Vistagen Therapeutics, Inc. \u2013 NASDAQ:VTGN", "summary": "The article displays the \"Price to book forward\" financial metric for Vistagen Therapeutics, Inc. (NASDAQ: VTGN) on the TradingView platform. It presents a simple table showing the period, value, change, and percentage change for this specific financial indicator. The content is ", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-03T04:10:41", "published_display": "03 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen (VTGN) CEO adds 36,818 ESPP shares, now holds over 54,000 directly", "summary": "Vistagen Therapeutics, Inc. President and CEO Shawn Singh acquired 36,818 shares of common stock through the company's Employee Stock Purchase Plan at $0.1921 per share. This acquisition, exempt under Rule 16b-3, increases his direct holdings to 54,846 shares. Additionally, 20,87", "url": "https://www.stocktitan.net/sec-filings/VTGN/form-4-vistagen-therapeutics-inc-insider-trading-activity-f4e1f526663d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:41", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen (VTGN) Chief Legal Officer adds 36,818 ESPP shares in Form 4 filing", "summary": "Vistagen Therapeutics' Chief Legal Officer, Reid G. Adler, increased his holdings by acquiring 36,818 shares of common stock through the company's 2019 Employee Stock Purchase Plan. This transaction, executed on June 30, 2026, at an average price of $0.1921 per share, was exempt ", "url": "https://www.stocktitan.net/sec-filings/VTGN/form-4-vistagen-therapeutics-inc-insider-trading-activity-32816654af87.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:41", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESPP grant gives Vistagen (NASDAQ: VTGN) CFO 11,712 new shares", "summary": "Vistagen Therapeutics, Inc.'s Chief Financial Officer, Nick B. Tressler, acquired 11,712 shares of common stock on June 30, 2026, through the company\u2019s 2019 Employee Stock Purchase Plan at $0.1921 per share. Following this transaction, his direct holdings amount to 11,712 shares,", "url": "https://www.stocktitan.net/sec-filings/VTGN/form-4-vistagen-therapeutics-inc-insider-trading-activity-0e64708fc868.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:41", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder", "summary": "Vistagen announced topline results from its PALISADE-4 Phase 3 trial for fasedienol, which did not meet primary or secondary endpoints for treating social anxiety disorder in the overall population. However, a post-hoc analysis showed statistically significant improvement in pati", "url": "https://finance.yahoo.com/healthcare/articles/vistagen-announces-topline-post-hoc-120000253.html", "source_name": "Market source", "published_at": "2026-07-01T22:39:52", "published_display": "01 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 33, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen\u2019s fasedienol fails second Phase III social anxiety trial, clouding acute treatment strategy", "summary": "Vistagen Therapeutics announced that its fasedienol candidate failed a second Phase III trial (PALISADE-4) for social anxiety disorder, again missing its primary endpoint. This result puts pressure on the company to identify a credible path forward with the FDA, especially as the", "url": "https://allsci.com/news/clinical-trials/vistagens-fasedienol-fails-second-phase-iii-social-anxiety-trial-clouding-acute-treatment-strategy/", "source_name": "AllSci", "published_at": "2026-07-01T09:41:26", "published_display": "01 Jul 2026 09:41", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Vistagen Therapeutics, Inc. (VTGN) on behalf of investors who purchased securities prior to April 1, 2024, and still hold them. The investigation aims to determine if Vistagen's officers and/or directors", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-vistagen-therapeutics-inc-0", "source_name": "The National Law Review", "published_at": "2026-07-01T07:39:22", "published_display": "01 Jul 2026 07:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss", "summary": "Vistagen Therapeutics' Phase 3 PALISADE-4 trial for its intranasal fasedienol in acute social anxiety disorder missed its primary and secondary endpoints. However, a post-hoc analysis identified a statistically significant benefit in patients with very severe social anxiety, prom", "url": "https://www.benzinga.com/news/health-care/26/06/60197274/penny-stock-vistagen-keeps-regulatory-plans-alive-despite-anxiety-study-miss", "source_name": "Benzinga", "published_at": "2026-06-30T17:10:57", "published_display": "30 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VistaGen Therapeutics, Inc. (VTGN) announced topline data and post-hoc analysis results from the Phase 3 clinical trial Palisade-4 of its candidate drug Fasedienol for the acute treatment of social anxiety disorder.", "summary": "VistaGen Therapeutics (VTGN) released topline data and post-hoc analysis results from its Phase 3 Palisade-4 trial for Fasedienol, a drug for acute social anxiety disorder. The trial, using a public speaking challenge model, did not show a statistically significant difference bet", "url": "https://www.bitget.com/amp/news/detail/12560605483694", "source_name": "Bitget", "published_at": "2026-06-30T14:39:21", "published_display": "30 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen (NASDAQ: VTGN) Phase 3 fasedienol trial misses main goal but shows severe-SAD signal", "summary": "Vistagen's Phase 3 PALISADE-4 trial for intranasal fasedienol in social anxiety disorder (SAD) missed its primary and secondary endpoints in the overall patient population. However, a post-hoc analysis revealed a nominally statistically significant improvement in a subgroup of pa", "url": "https://www.stocktitan.net/sec-filings/VTGN/8-k-vistagen-therapeutics-inc-reports-material-event-e81fcc1b20bb.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:10:57", "published_display": "30 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen reports PALISADE-4 miss on primary endpoints; positive post-hoc signal in very severe SAD subgroup", "summary": "Vistagen (VTGN) announced that its PALISADE-4 trial did not meet its primary or secondary endpoints for social anxiety disorder (SAD). However, a post-hoc analysis revealed a nominally significant benefit in a subgroup of patients with very severe SAD. The company plans to engage", "url": "https://www.tradingview.com/news/tradingview:60eda03715aed:0-vistagen-reports-palisade-4-miss-on-primary-endpoints-positive-post-hoc-signal-in-very-severe-sad-subgroup/", "source_name": "TradingView", "published_at": "2026-06-30T12:10:57", "published_display": "30 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen fails another phase 3 anxiety trial, spies path forward", "summary": "Vistagen's social anxiety disorder drug candidate, fasedienol, has failed another phase 3 trial, PALISADE-4, missing its primary and secondary endpoints. Despite the setback, the company plans to pursue FDA approval by leveraging post hoc analysis data from a subpopulation of pat", "url": "https://www.fiercebiotech.com/biotech/vistagen-fails-another-phase-3-social-anxiety-trial-spies-path-market", "source_name": "Fierce Biotech", "published_at": "2026-06-30T09:48:00", "published_display": "30 Jun 2026 09:48", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen\u2019s fasedienol fails main test, but one subgroup showed a signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPaXFETmU1NERHdFBZYzV3T1EtcGRoaXhDYnZySFBZM1ZLV2RZenVYUjBnU001MGtsSGF4SW5WS3pzVFNPanZhYzJUeHhYMlNoZHJMZ1hfMGJXa2toaUR1ZG10ZHZSckhfck0wMWpjRjF3SjZ0ZmRMOXdnSzN0b3FiN3JsLUZsVHctXzAtbUlyYU92QzExUGc3VHFRUmdna1ZWOERxNnRkZGUtRVdCd2pJQlBHN2RsS0N3eGo5YmZKRko?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics, Inc. Actuals & Estimates (NASDAQ:VTGN)", "summary": "This article provides an overview of Vistagen Therapeutics, Inc. (VTGN) financial actuals and analyst estimates, including its current stock price, market capitalization, and historical performance. It also details quarterly earnings, revenue, and future earnings report dates. Th", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T17:40:15", "published_display": "26 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics, Inc. Actuals & Estimates (BOATS:VTGN)", "summary": "This article provides financial actuals and estimates for Vistagen Therapeutics, Inc. (VTGN) on the BOATS exchange, including analyst forecasts, historical price data, and upcoming earnings information. It details the company's financial performance, such as recent earnings and r", "url": "https://www.tradingview.com/symbols/BOATS-VTGN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T05:39:38", "published_display": "26 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VTGN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Vistagen Therapeutics, Inc. (VTGN) stock, including analyst price targets and ratings. It details current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings information. The report also addre", "url": "https://www.tradingview.com/symbols/NASDAQ-VTGN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T19:10:19", "published_display": "25 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics\u2019 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth", "summary": "Vistagen Therapeutics Inc. is facing increased execution risks due to its planned March 2026 workforce reduction, which aimed to conserve cash and advance trials for fasedienol. This downsizing could lead to a loss of institutional knowledge, lower employee morale, and hinder the", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VTGN-Q/pressreleases/2528780/vistagen-therapeutics-2026-workforce-cuts-raise-execution-risks-and-threaten-long-term-growth/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T03:09:16", "published_display": "19 Jun 2026 03:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics directors to step down after 2026 annual meeting", "summary": "Vistagen Therapeutics announced that two board members, Margaret FitzPatrick and Dr. Joanne Curley, will not seek re-election at the company\u2019s 2026 Annual Meeting of Stockholders. Both will continue to serve until their terms conclude at the meeting. This news follows a period of", "url": "https://m.uk.investing.com/news/sec-filings/vistagen-therapeutics-directors-to-step-down-after-2026-annual-meeting-93CH-4734114?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T02:39:33", "published_display": "18 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Vistagen Therapeutics (NASDAQ:VTGN) Must Use Its Cash Wisely", "summary": "Vistagen Therapeutics (NASDAQ:VTGN) is burning through cash at a concerning rate, with a cash burn of US$61m against US$45m in reserves as of March 2026, giving it only about 9 months of cash runway. The company's cash burn increased by 43% last year, and its cash burn relative t", "url": "https://www.sahmcapital.com/news/content/heres-why-vistagen-therapeutics-nasdaqvtgn-must-use-its-cash-wisely-2026-06-17", "source_name": "Sahm", "published_at": "2026-06-18T02:39:32", "published_display": "18 Jun 2026 02:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Vistagen Therapeutics Inc (VTGN). It notes that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents curr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vtgn/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T01:00:17", "published_display": "18 Jun 2026 01:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting", "summary": "Vistagen Therapeutics, Inc. announced that two of its board members, Margaret FitzPatrick and Dr. Joanne Curley, will not seek re-election at the company's 2026 Annual Meeting of Stockholders. Both directors will continue to serve until their current terms conclude at the meeting", "url": "https://www.stocktitan.net/sec-filings/VTGN/8-k-vistagen-therapeutics-inc-reports-material-event-c05f165242e7.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:40:17", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOb2o0TkhvdXBJa1JJc0lIZWZpelZWbmlaVkEzbjhlOVd4aWRJcE13V2hHX2F3Q3duV2lqNFl0eEJhX21PRGYtTjRIV3RnYmhjeDUxeS16aDhFa0RJY3BsTFNSQzhESG5nZ0ptN0hCc01LYTl5aFYwMTR1cWdqdmtMa3BFNXVYRUhqek5mT0prbHNtOWNiaTZJQjBEOHNOVm9tN3JjV3ozLVdiXzZ1UHRsM2llcmM2X2N3UkRPMzlVOXFaQlprbjZqbkowM1dTdUc1dUdGZA?oc=5", "source_name": "Business Wire", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 data for Vistagen intranasal anxiety drug due this month", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQX1JwYmFpMDRZNXBRUVk5aDdGcVJ6UEZtb2tVN2FmbVlMR1k3Zk1ISThyaTNGaUxNUDB5aGRHdEcwclJjaUpGUTBpYlRyTzctakxHcjM3a0RidlZPVExRb1BSQ2tzbUtudGhBN3NCUmxzVmc4alJlS3ROUjBWTWtXWnc2U2ttclNDMHgwQy1mT3U1Z3g0RUFIQS1BOVM2VW1HbEhTcjFEZHRDczd1bkFLMmh4VFFjVDJkdk5n?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings | VTGN Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOcGpPZXNfNFV3Q2VXNlBNSHc0NEJZVUJ2bVBCNy1PczZYZzRjS2xsdUdiQU9IaFVyT2VnUlFrYnVRdmJjREtpaXdZc2ZfLUYtN3ZuWE1LeFJRU0lBSm1oTjZvdFdaUF9WV0ZqQnlPcGRoTDFqSzhvUlVRYVNFTmJfT2o0ckhxWVBNWmE5RmRmQU9WZw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics Says Fasedienol Clinical Program Exceeds ICH Exposure Thresholds", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vistagen-therapeutics-says-fasedienol-clinical-103808726.html", "source_name": "MT Newswires", "published_at": "2026-06-10T10:38:08+00:00", "published_display": "10 Jun 2026 10:38", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/vistagen-achieves-minimum-ich-safety-123000936.html", "source_name": "Business Wire", "published_at": "2026-06-09T12:30:00+00:00", "published_display": "09 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPNUdmU3B4MGNqVkY5SlUtbW9nUHhXSVNtZkowWlJsUVZ5ZjhjQkplSzJiZWtjeW1CM0tPb0xCREk4RUxGQ1Z6WGFTWWdLbHdMb21XRGtDZlo2MUtCaks5OTYta2NFR1huT0tYYVFHdFhHSGFxRklVMEQ2UDZpeS0xaVB3bkJ1QlVjcldOWGU1S1BITUNfSUI4R2FPMUluQ1FkcWc1STFvX3hyTGdMVWc5RGctQVA?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNOGo1Q0hGV3Y3R3VweGdwUDlGN1lScU1MUUIwLXZTV2pLRmNLYm96VEV5cEF4aExlY3FnYktFSzhJSXpwTlhYNHVKQnhtaU9zSlNfX0xBVTlwMUF5LXFFdHRmLUZORjV0MXY0eW5BNjI0ZXlLek9FNklvRVRMMXFZZ19oWklScXhGRjBwTGQzeTNTc3RlX2o0a1VmOU1GaUVjVVh5WmNxaEtzNXRC?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Public-speaking challenge study ends; Vistagen data due this quarter", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPWVRQTzBhdzVSVV9VUDZ1LXRadjZ6Uy1ONFF0bFgwci1xMC1zRFhnc1QtT2NPelh5elB6aEY3VnF2djcxb0tVd21NMkFKUGtxY2dCTXFETHh0OUNveDc1Mk5ZWldfUjZMUlF1Tl92SWozUEIwNm9tcUxPaDJhMlJkeC1zZ1MwZ080M0ViLTAtSUlRNWxuTW9NaTM5VjVtZ29nQnJWdmcyc2I1X0RQUWhwNHhLQnd0bDNhM3o3Tg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5IMlg1RGl0WjdTMF94MjFhZ2lkS0x0M1FyUTliTjBZbkNuNEtuOFF6ZmdqTno2Ty1vZkxyMGwwV3FfOU1pOUlBM1JoUndaV1U3TkhvZ2N3Yk1SVHc3?oc=5", "source_name": "Schubert Jonckheer & Kolbe", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwJBVV95cUxNSHYybTdtTUVRZUdIVFh0Z0FNak5ZNE1WaEhPRTRPNEM1ajU2eG5zOFVLV3NXbkpfZ0lfR1NLWGVtV0VHTEc3MXE0RS1tM0NDV1p3ckduSjRkYkJPN0FQOFMtZ0ZaVENhaHdCaTJVY0RuNHZhSnBOWDNJTE1SYXdKNjJfbDliMEdXRGt2NFdYSHplQjc0bzZMMzctcE5LTkpSQ1o4TVhBSjdIRVZYdWgtUHdwc2pyWVpaMi1mNEl3RUw2VU1jYkRmYzZSa3NndnZ1dUUwd2NieVNGQUd5QUVmVXRmNGk5b3N5T050aGhNa0lzbmNYTzlXZGJYSmpVa19xek8zNUxEUXZqbDBmOUxCYURXdWpmdnNJbml1RXZpYVdCaW4yb25JWHJEaXFPQllheEduMVpoUHlndGM?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQQVJsNjJkX2NUSzRGNU02SnYzV2tzRVA4ZzRJTHZTQkZKMkxMSXctRzNzUWFsWTltckFkU0dvVTBZM2NUVEplZUxaSEVtVTJadGZZQ0w5MEdOQ0ZxLU0zUkI5d1BsUVpPekt0Y1R4aXVyclNUeTJzcjA5bzdWYlFTenFkRnd4YzA0bUVvbA?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vistagen Stock Tank 82% Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVEZvZGVsN2tpeS1KVnM5YmxlYUtYUGlRc2hVR0F2ZTB6djlLOEZESXdkRDRHM3E3cUFBVHdYeFo0MVZzemlHU1BRa00zS2ZTd2M0OEJRVVU4enZtM3h2NVdYQVVWTWlKTjl6RWJOcHNyME1UZnJvWWM5STN6aFpfVEZQMFNmUUJjdnBJSUM0T1phNFJhSHEyMkpkNnFRZw?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-17T16:02:41+00:00", "published_display": "17 Dec 2025 16:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 (NASDAQ:VTGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQbUdVRG02WGgxenQwVVhOWUFNSTMweDBRYnhKVUUtakJNai1yZWJrQTJ4dkZINEhHNmpNOVd2VlF5cFdfekl3UjR0NWtkTGlqdm4yeGFRUGdqLXhQaHRhT0RJNThta1YwRV9Jc1lhaU1uQzRFWlI2Z1ZGWngtbWdOaVBGS2JUeWtTVy1DQmJhaENrZHdVX1BBQkgwc1BJZGVuM0xwNVV6ZDJXY1k?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-18T08:00:00+00:00", "published_display": "18 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS0IzUlV4clR6V0tyRDlPVm45anhrRGtPZ2tHX1lZMFIwYmF6RWk0Q0dOMXQ4UHV5QWVMeTlFS2hteVd3YkRmMjUwRm1HWGdnalgwS1M0TFhDa3RUSTVYbnJXMWhOUzZoLXNQSXBkQkxYR1BycHVFOENxRm5CNG9tTTBCTXpCYUxpeHBHYnE4VUFTbTVLUEM3QjhCMGFWZWFHT3ZlM0M3SWUxZDFMMUQ0a0YwY1h5R19GSWVUV3Vn?oc=5", "source_name": "BioSpace", "published_at": "2025-06-17T07:00:00+00:00", "published_display": "17 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics (VTGN) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9wbEJrb2FRZnYyOWtqaDlsdnQwdy1BcEM3Sl8xWUJtR1FvWnBnUWZrT2hYbUNLT3FsQ3A0dlBkRjFTTWVGQXM2eXlZRkIxT3JwTTdB?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:34:57+00:00", "published_display": "25 Apr 2025 01:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxOUkxlTFFYXzVRYXFpWkh1N21UTDNSNzRLTGU4R1pfUmpGcmZsbTlyZi1KUmE0RzVIa05UZlhJZ3JlSk0tRFliQ2NSeGtzVzUydzN4WFVKZVMxdTFaaEVtM0lfdmFzUFl3VXJKXzdUWlAyZHZsSWlKMGNTNWtrOW5ZWm1ob3ZDWG5oRzRwbkJ5VmxoWVZBSVg0MlZVc3M2TjNpRnhSZml5T2FZOUljYTdTUEdocDRuV19oaG52TmxfdEJxZC1uLTJNY0xpSjlQQWdzbVYzWldjd0lZdHlNcFliUEhyOFRTeTdJVk44MmpVdnF0NFhueFRWYkFZZ1pTRGxpcHhUMktuS19hZw?oc=5", "source_name": "PR Newswire", "published_at": "2020-08-10T07:00:00+00:00", "published_display": "10 Aug 2020 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vistagen Therapeutics (VTGN) Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1heUpFTmhRcC0zR3A2blVoQUxnUF84MkhuNWpHcEVOMEhmOGdlR0pOUEg1SkxSUDNSOTBHYWUxV0FPTEJyQ1JBaVVJVjBhdw?oc=5", "source_name": "Stock Titan", "published_at": "2020-08-08T11:57:33+00:00", "published_display": "08 Aug 2020 11:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 53, "sentiment_summary": {"positive": 2, "negative": 16, "neutral": 35, "score": 42, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 11.0, "count": 22}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 16}, "market_context": {"has_market_context": true, "latest_close": 0.26, "latest_week": "2026-07-10", "one_week_move": 3.7, "four_week_move": -55.2, "twelve_week_move": -58.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.672399, "market_dynamics_buy_signal": false, "relative_strength": -88.67699, "fair_value_gap": -91.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.5209, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.7% over one week, -55.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 10}, {"label": "TradingView", "count": 7}, {"label": "Stocktwits", "count": 2}, {"label": "Business Wire", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 22}, {"label": "Regulatory and legal", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "42/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+3.7% over one week, -55.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?"}], "updated_at": "2026-07-18T09:47:21.806295+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}